Cytosorbents Corporation (NASDAQ:CTSO) is scheduled to be releasing its earnings data after the market closes on Monday, November 6th. Analysts expect Cytosorbents Corporation to post earnings of ($0.07) per share for the quarter.

Cytosorbents Corporation (NASDAQ:CTSO) last issued its quarterly earnings results on Monday, August 7th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. Cytosorbents Corporation had a negative return on equity of 529.95% and a negative net margin of 80.56%. The firm had revenue of $3.57 million for the quarter, compared to analysts’ expectations of $3.29 million. On average, analysts expect Cytosorbents Corporation to post $-0.29 EPS for the current fiscal year and $-0.38 EPS for the next fiscal year.

Shares of Cytosorbents Corporation (CTSO) opened at 6.20 on Monday. The stock’s market cap is $174.42 million. Cytosorbents Corporation has a one year low of $3.30 and a one year high of $6.70. The firm has a 50-day moving average price of $5.92 and a 200-day moving average price of $4.95.

CTSO has been the topic of several analyst reports. Aegis restated a “buy” rating and issued a $9.00 price target on shares of Cytosorbents Corporation in a research note on Tuesday, July 25th. Maxim Group restated a “buy” rating and issued a $10.00 price target on shares of Cytosorbents Corporation in a research note on Wednesday, July 5th. ValuEngine upgraded shares of Cytosorbents Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Cytosorbents Corporation in a research note on Tuesday, September 26th. Finally, B. Riley restated a “buy” rating and issued a $11.25 price target on shares of Cytosorbents Corporation in a research note on Saturday, August 12th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Cytosorbents Corporation presently has a consensus rating of “Buy” and a consensus target price of $10.45.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/30/cytosorbents-corporation-ctso-set-to-announce-earnings-on-monday.html.

About Cytosorbents Corporation

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Earnings History for Cytosorbents Corporation (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.